TWO · 7729.TWO
Steminent Biotherapeutics Inc.
NT$177.00+NT$2.50 (+1.43%)
Steminent Biotherapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.25% below the high.
Loading market information…
TWO · 6934.TWO · TWD
Stock price
Quote as of Jan 30, 2026, 06:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Hcmed’s quoted price sits in the upper half of its reported 52-week range, 11.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
HCmed Innovations Co Ltd. specializes in creating advanced solutions for respiratory treatment through the application of mesh technology. Their product line features devices such as Pulmogine and AdheResp. Beyond its core offerings, the company delivers extensive analytical services focused on aerosol characterization, helping clients optimize and develop new inhaled therapeutic products. This analytical assistance is provided in strict adherence to Pharmacopoeia standards. Founded on October 6, 2014, by Jason Cheng, Leon Tsai, Shaogi Huang, and Simon Hsieh, HCmed maintains its principal office in Taipei, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$177.00+NT$2.50 (+1.43%)
Steminent Biotherapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.25% below the high.
NT$32.30-NT$1.10 (-3.29%)
Chunghwa Chemical Synthesis & Biotech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.82% below the high.
NT$21.30-NT$0.15 (-0.7%)
GlycoNex Incorporation’s quoted price sits in the lower half of its reported 52-week range, 29.0% below the high.
NT$29.45NT$0.00 (0.0%)
Genomics BioSci & Tech. Co.,Ltd.’s quoted price sits in the upper half of its reported 52-week range, 20.08% below the high.
NT$20.80-NT$0.30 (-1.42%)
Gwo Xi Stem Cell Applied Technology Co. , Ltd’s quoted price sits in the lower half of its reported 52-week range, 28.03% below the high.
NT$9.42-NT$0.25 (-2.59%)
Sunny Pharmtech Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.54% below the high.
NT$23.00-NT$1.05 (-4.37%)
Advagene Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.38% below the high.
NT$57.80-NT$0.60 (-1.03%)
Greenyn Biotechnology Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 25.9% below the high.
